Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib cardiovascular outcomes phase 3 trial in inadequately controlled ASCVD
MOH_2022-04-07_010660Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Feb 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Obicetrapib 10 mg once daily with Matching placebo (2 arms). Primary endpoint: Major adverse cardiovascular events. Started Feb 2022; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on MOH_2022-04-07_010660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-07_010660.